Virologic, immunologic, and clinical response to highly active antiretroviral therapy: The gender issue revisited

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 4, 2003, Pages 452-461

  Moore, Antonia L ^a   Kirk, Ole ^b   Johnson, Anne M ^a   Katlama, Christine ^c   Blaxhult, Anders ^d   Dietrich, Manfred ^e   Colebunders, Robert ^f   Chiesi, Antonio ^g   Lungren, Jens D ^b   Phillips, Andrew N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^e DEPARTMENT OF CARDIOLOGY   (Germany)

^f INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

CD4 count; Clinical progression; Gender; HAART; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EUROPE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX CHARACTERISTICS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0037378569     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200304010-00017     Document Type: Article

References (42)

1. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA study group. Lancet 1998;352:1725-30.
2. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study, Swiss HIV Cohort Study. BMJ 1997;315:1194-9.
3. Palella FJ Jr, Delaney KM, Moorman AC. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Eng J Med 1998;338:853-60.
4. Communicable Disease Report Weekly, AIDS and HIV in the United Kingdom: monthly report. 25th January 2001. Volume 11, number 4.
5. UNAIDS Joint United Nations Program on HIV/AIDS: Summary of the HIV/AIDS epidemic, December 1998. Geneva.
6. Sabin CA, Phillips AN. Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. J Antimicrobial Chemotherapy 2001;47:371-5.
7. Lundgren JD, Pedersen C, Clumeck N, et al. Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ 1994;308:1068-73.
8. Reeves GK, Overton SE. Preliminary survival analysis of UK AIDS data [letter]. Lancet 1988,I:880.
9. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998;352: 1510-14.
10. Anastos K, Gange SJ, Lau B, et al. Association of race and gender with HIV-I RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000;24:218-26.
11. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS 1999;13:2361-4.
12. Buira E, Gatell JM, Miro JM, et al. Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients. J Acquir Immune Defic Syndr Hum Retrovirol 1992;5:737-42.
13. Junghans C, Ledergerber B, Chan P. et al. Sex differences in HIV-1 viral load and progression to AIDS. Swiss HIV cohort study. Lancet 1999;353:589.
14. Evans JS, Nims T, Cooley J, et al. Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. J Infect Dis 1997;175:795-800.
15. Chaisson RE, Keruly JC, Moore RD. Race, sex drug use and progression of Human Immunodeficiency virus disease. N Engl J Med 1995;333:751-6.
16. Cozzi Lepri A, Pezzotti P, Dorrucci M, et al. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study, BMJ 1994;309: 1537-42.
17. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV infection. Ann Intern Med 1997; 126:946-54.
18. Vlahov D, Graham NMH, Hoover D, et al. Prognostic indicators for AIDS and infectious disease and death in HIV-infected injection drug users: plasma viral load and CD4 cell count. JAMA 1998;279:35-40.
19. Montaner J, de Masi R, Hill A, and the Caesar Coordinating Committee: Validation of HIV-1 RNA and CD4 count as surrogate markers in the Caesar trial [abstract 207]. 6th European Conference on Clinical Aspects and Treatment of HIV infection; October 11-15, 1997: Hamburg.
20. Cozzi Lepri A, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS 1998;12:1639-43.
21. Centers for Disease Control and Prevention. Revision of the AIDS Case Definition, 1993. Atlanta, Georgia: 173-5.
22. Staszewski S, Miller V, Sabin C. et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999;13: 367-73.
23. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: prospective multicentre study, Swiss HIV cohort Study. BMJ 1997;315:1194-9.
24. Valdez H, Lederman MM, Woolley I, et al. Human Immunodeficiency Virus 1 protease inhibitors in clinical practice - predictors of virological outcome. Arch Intent Med 1999;159:1771-6.
25. Friis-Moller N. O Kirk, A Mocroft, et al. Admission to hospital in the HAART era: the EuroSIDA study [abstract P410]. Fifth International Congress on Drug Therapy in HIV Infection; October, 2000; Glasgow.
26. Sterling TR, Lyles CM, Vlahov D, et al. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999;180:666-72.
27. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human' immunodeficiency virus infection and CD4 cell counts of 200 per cubic milliliter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
28. Gullick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-39.
29. Montaner JSG, Reiss P, Cooper DA, et al. A randomized double blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada, Australia study. JAMA 1998;279: 930-37.
30. British HIV Association (BHIVA) Guidelines 2001 draft. Available at: http://www.aidsmap.com
31. US Health & Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. April 2001.
32. Delmas MC, Jadand C, de Vincenzi I, et al. Gender difference in CD4 cell counts persist after HIV infection. SERCO study group. AIDS 1997;11:1071-3.
33. Maini MK, Cilson RJC, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med 1996;72:27-31.
34. Tollerud DJ, Clark JW, Brown LM, et al. The influence of age, race and gender on peripheral blood mononuclear cell subsets in healthy non-smokers. J Clin Immunol 1989;9:214-22.
35. Multicohort Analysis Project Workshop. Part II, Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and B2 microglobulin are not adequate to estimate time of HIV infection. AIDS 1994;8:923-33.
36. Reichert T, De Bruyere M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 1991;60:190-208.
37. Mocroft A, Kirk O, Barton SE, et al. Anemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999;13: 943-50.
38. Hasheeve D, Salvato P. Thompson C. Frequency of opportunistic infections (OIs) and risk of death by gender and ethnicity [abstract Tu.B.2336]. International Conference on AIDS; 1996.
39. Fleming PL, Ciesielski CA, Byers RH, et al. Gender differences in reported AIDS-indicative diagnoses. J Infect Dis 1993;168:61-7.
40. Currier JS, Spino C, Grimes J, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000;24:316-24.
41. d'Arminio Monforte A, Lepri AC, Rezza G. et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral-naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-naïve Patients. AIDS 2000;14:499-507.
42. Hogg RS, Strathdee SA, Craib KJP, et al. Lower socioeconomic status and shorter survival following HIV infection. Lancet 1994: 344:1120-4.